Bausch + Lomb said today that it won FDA 510(k) clearance for the use of Tangible Hydra-PEG contact lens coating on new devices, now cleared for use with lenses made from its Boston gas permeable materials. The new clearance will allow the Bridgewater, N.J.-based company to use the coating on its Boston XO, Boston XO2, […]
Bausch + Lomb
Analyst downgrades pressure medtech stocks
Several medical device companies took hits yesterday after analysts on Wall Street downgraded their stocks, on a day when the major market indices each closed up a hair, and even medtech firms that enjoyed upgrades came under pressure. Globus Medical (NYSE:GMED) suffered the most after Morgan Stanley analyst David Lewis cut his rating on the stock from […]
Systemic therapy beats Bausch & Lomb implant in NIH uveitis study
Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]
Bausch & Lomb wins FDA 510(k) for Vitesse open-port vitrectomy system
Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiary Bausch & Lomb said today it won FDA 510(k) clearance for its Vitesse hypersonic open port vitrectomy system. The Bridgewater, N.J.-based company touted the newly cleared system as the 1st and only hypersonic 100% open port vitrectomy system, and said it will be exclusively available on the Stellaris Elite vision enhancement […]
Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017
Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]
FDA clears Bausch & Lomb’s Stellaris Elite cataract system
Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiary Bausch & Lomb said today it won FDA 510(k) clearance for its Stellaris Elite vision enhancement system. The system is a next-gen phacoemulsification cataract platform designed for cataract lens removal, and offers improved customization and precise aspiration control with predictive infusion management, Bausch & Lomb said. “We are pleased to continue […]
Haemonetics taps ex-Medtronic CIO Burke as new CFO | Personnel Moves August 4, 2016
Haemonetics taps ex-Medtronic CIO Burke as new CFO Haemonetics (NYSE:HAE) said this week it tapped former Medtronic (NYSE:MDT) chief integration officer William Burke as its new chief financial officer, effective August 8. Burker operated as CIO with Medtronic since 2015, serving during the integration of Covidien. Prior to that, he held various finance positions with […]
Inside Valeant’s ambitious plan for its contact lens business
(Reuters) — Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) has pursued a plan in recent months to dominate the market for specialty contact lenses, according to 2 people familiar with the company’s approach and some of the company’s communications with its customers. The Canadian drugmaker’s goal, spelled out to key employees and demonstrated through its actions, has been to acquire […]
Justice Dept., FTC probe Valeant’s Bausch & Lomb, Paragon lens operations
The U.S. Justice Dept. and the Federal Trade Commission are investigating Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiaries Bausch & Lomb and Paragon Vision Sciences, the Canadian drug maker said yesterday. The Justice Dept. is looking into payments Bausch & Lomb made to doctors using its Crystalens intra-ocular lens and Victus eye laser, Valeant said yesterday in a regulatory […]
China fines J&J and other contact lens makers for anti-trust violations
Chinese regulators slapped a string of contact lens and eyeglass makers with more than $3 million (19 million yuan) in fines after accusing them of violating the country’s anti-trust laws.
Valeant confirms $9B acquisition of Bausch & Lomb
